SOURCE: SECFilings.com

SECFilings.com

November 14, 2016 09:00 ET

How New Technologies Could Revolutionize Drug Discovery -- SECFilings.com

REDONDO BEACH, CA--(Marketwired - Nov 14, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing several new technologies that may decrease the prohibitive costs typically associated with drug discovery. Included in the report is Endonovo Therapeutics (OTCQB: ENDV) and its Cytotronics™ drug development platform based on bioelectronics technology.

The cost to develop a new pharmaceutical drug has more than doubled over the past ten years to $2.6 billion, according to the Tufts Center for the Study of Drug Development, including an average out-of-pocket cost of $1.4 billion and an estimated $1.2 billion in returns that investors forego in the 10+ years that a drug candidate spends in development. These numbers don't include the $300+ million spent on post-approval costs like dosing and formulation.

These high costs make a drug failure extremely detrimental to a company's financial outlook, particularly if it's a late-stage drug candidate. When drugs are approved, these high development costs also translate to higher costs for patients since drug companies must recoup the cost of the clinical trials (along with any failed drugs) within a patent window. Drug pricing, in many ways, is based on R&D costs rather than the value to patients.

Endonovo's Cytotronics™ is being developed as a high-fidelity drug development and toxicology testing platform designed to catch problems early on. The platform uses bioelectronics to effectively grow and maintain three dimensional tissue/cell cultures for up to 180 days. Biotech firms can use these cell cultures to conduct toxicology testing to catch problems early on to avoid spending money to develop a toxic drug.

"A Phase I trial can cost roughly $15 million and take several years to complete and over 40% of marketing candidate drugs are terminated as a result of unexpected toxic effects," said Alan Collier, Endonovo's CEO. "We are developing our Cytotronics platform to be a high-fidelity system enabling drug and cosmetic products to be tested for their ADME and toxicity. Our ultimate goal focuses on lowering drug development cost while increasing safety."

Read the full article here: http://analysis.secfilings.com/articles/123-how-new-technologies-could-revolutionize-drug-discovery

About SECFilings.com
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

Contact Information